{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:59:37Z","timestamp":1772114377036,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,7,7]],"date-time":"2014-07-07T00:00:00Z","timestamp":1404691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"},{"start":{"date-parts":[[2014,7,7]],"date-time":"2014-07-07T00:00:00Z","timestamp":1404691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The molecular drivers of thymoma are poorly understood. Outside of the identification of rarely occurring epidermal growth factor receptor and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog mutations via candidate gene sequencing, mutations in common cancer genes have yet to be observed. Only a single thymoma genome sequence has been previously reported, with no mutations in known cancer genes identified. Thus, we attempted to identify somatic driver mutations in a cytogenetically normal thymoma. A stage IVB type B3 thymoma from a 47-year-old male of Asian descent with no history of myasthenia gravis or other autoimmune condition was genomically evaluated. Exome sequencing and low-pass whole-genome sequencing was performed to identify somatic point mutations, copy number changes and structural variants. Mutations in known tumor suppressors DNMT3A (p.G728D) and ASXL1 (p.E657fs), consistent with mutations of known consequence in acute myeloid leukemia, were identified. Contrary to a previous report, this finding suggests the genetic etiology of thymomas may not be fundamentally distinct from other tumor types. Rather, these findings suggest that further sequencing of cytogenetically normal thymoma samples should reveal the specific molecular drivers of thymoma.<\/jats:p>","DOI":"10.1038\/oncsis.2014.25","type":"journal-article","created":{"date-parts":[[2014,7,7]],"date-time":"2014-07-07T13:18:53Z","timestamp":1404739133000},"page":"e111-e111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["ASXL1 and DNMT3A mutation in a cytogenetically normal B3 thymoma"],"prefix":"10.1038","volume":"3","author":[{"given":"R","family":"Belani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G A","family":"Erikson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M S","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J K","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W J","family":"Shipman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S M","family":"Haaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Torkamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,7]]},"reference":[{"key":"BFoncsis201425_CR1","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1200\/JCO.1999.17.7.2280","volume":"17","author":"CR Thomas","year":"1999","unstructured":"Thomas CR, Wright CD, Loehrer PJ . Thymoma: state of the art. J Clin Oncol 1999; 17: 2280\u20132289.","journal-title":"J Clin Oncol"},{"key":"BFoncsis201425_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-642-60157-6","volume-title":"Histological Typing of Tumours of the Thymus","author":"J Rosai","year":"1999","unstructured":"Rosai J, Sobin LH . Histological Typing of Tumours of the Thymus. Springer, Berlin; New York, 1999, pp 65."},{"key":"BFoncsis201425_CR3","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","volume":"48","author":"A Masaoka","year":"1981","unstructured":"Masaoka A, Monden Y, Nakahara K, Tanioka T . Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485\u20132492.","journal-title":"Cancer"},{"key":"BFoncsis201425_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/JTO.0b013e31802bafc8","volume":"2","author":"K Yokoi","year":"2007","unstructured":"Yokoi K, Matsuguma H, Nakahara R, Kondo T, Kamiyama Y, Mori K et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2007; 2: 73\u201378.","journal-title":"J Thorac Oncol"},{"key":"BFoncsis201425_CR5","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","volume":"12","author":"PJ Loehrer Sr.","year":"1994","unstructured":"Loehrer PJ Sr., Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group. Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994; 12: 1164\u20131168.","journal-title":"J Clin Oncol"},{"key":"BFoncsis201425_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","volume":"68","author":"A Fornasiero","year":"1991","unstructured":"Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabro F et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991; 68: 30\u201333.","journal-title":"Cancer"},{"key":"BFoncsis201425_CR7","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","volume":"29","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G . Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011; 29: 4820\u20134827.","journal-title":"J Clin Oncol"},{"key":"BFoncsis201425_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0003-4975(95)00983-3","volume":"61","author":"K Yagi","year":"1996","unstructured":"Yagi K, Hirata T, Fukuse T, Yokomise H, Inui K, Ike O et al. Surgical treatment for invasive thymoma, especially when the superior vena cava is invaded. Ann Thorac Surg 1996; 61: 521\u2013524.","journal-title":"Ann Thorac Surg"},{"key":"BFoncsis201425_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/(SICI)1096-9098(199609)63:1<17::AID-JSO4>3.0.CO;2-T","volume":"63","author":"E Akaogi","year":"1996","unstructured":"Akaogi E, Ohara K, Mitsui K, Onizuka M, Ishikawa S, Mitsui T et al. Preoperative radiotherapy and surgery for advanced thymoma with invasion to the great vessels. J Surg Oncol 1996; 63: 17\u201322.","journal-title":"J Surg Oncol"},{"key":"BFoncsis201425_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","volume":"62","author":"K Yoh","year":"2008","unstructured":"Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008; 62: 316\u2013320.","journal-title":"Lung Cancer"},{"issue":"10 Suppl 4","key":"BFoncsis201425_CR11","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.1097\/JTO.0b013e3181f21114","volume":"5","author":"A Rajan","year":"2010","unstructured":"Rajan A, Giaccone G . Targeted therapy for advanced thymic tumors. J Thorac Oncol 2010; 5 (10 Suppl 4): S361\u2013S364.","journal-title":"J Thorac Oncol"},{"key":"BFoncsis201425_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.6004\/jnccn.2013.0073","volume":"11","author":"RJ Kelly","year":"2013","unstructured":"Kelly RJ . Thymoma versus thymic carcinoma: differences in biology impacting treatment. J Natl Compr Cancer Network 2013; 11: 577\u2013583.","journal-title":"J Natl Compr Cancer Network"},{"key":"BFoncsis201425_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0002-9440(10)64536-1","volume":"157","author":"A Zettl","year":"2000","unstructured":"Zettl A, Strobel P, Wagner K, Katzenberger T, Ott G, Rosenwald A et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000; 157: 257\u2013266.","journal-title":"Am J Pathol"},{"key":"BFoncsis201425_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/S0002-9440(10)64426-4","volume":"161","author":"M Inoue","year":"2002","unstructured":"Inoue M, Marx A, Zettl A, Strobel P, Muller-Hermelink HK, Starostik P . Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 2002; 161: 1507\u20131513.","journal-title":"Am J Pathol"},{"key":"BFoncsis201425_CR15","doi-asserted-by":"publisher","first-page":"e60572","DOI":"10.1371\/journal.pone.0060572","volume":"8","author":"I Petrini","year":"2013","unstructured":"Petrini I, Rajan A, Pham T, Voeller D, Davis S, Gao J et al. Whole genome and transcriptome sequencing of a B3 thymoma. PLoS ONE 2013; 8: e60572.","journal-title":"PLoS ONE"},{"key":"BFoncsis201425_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","volume":"99","author":"M Okano","year":"1999","unstructured":"Okano M, Bell DW, Haber DA, Li E . DN A methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247\u2013257.","journal-title":"Cell"},{"key":"BFoncsis201425_CR17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333\u2013339.","journal-title":"Nature"},{"key":"BFoncsis201425_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nrc1299","volume":"4","author":"PA Futreal","year":"2004","unstructured":"Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177\u2013183.","journal-title":"Nat Rev Cancer"},{"key":"BFoncsis201425_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature06146","volume":"449","author":"D Jia","year":"2007","unstructured":"Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X . Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007; 449: 248\u2013251.","journal-title":"Nature"},{"key":"BFoncsis201425_CR20","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer Genome Atlas Research N","year":"2013","unstructured":"Cancer Genome Atlas Research N, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med 2013; 368: 2059\u20132074.","journal-title":"New Engl J Med"},{"key":"BFoncsis201425_CR21","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. New Engl J Med 2010; 363: 2424\u20132433.","journal-title":"New Engl J Med"},{"key":"BFoncsis201425_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/blood-2011-07-369934","volume":"119","author":"HA Hou","year":"2012","unstructured":"Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012; 119: 559\u2013568.","journal-title":"Blood"},{"key":"BFoncsis201425_CR23","doi-asserted-by":"publisher","first-page":"30941","DOI":"10.1074\/jbc.M112.366625","volume":"287","author":"C Holz-Schietinger","year":"2012","unstructured":"Holz-Schietinger C, Matje DM, Reich NO . Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem 2012; 287: 30941\u201330951.","journal-title":"J Biol Chem"},{"key":"BFoncsis201425_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","volume":"22","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22: 180\u2013193.","journal-title":"Cancer Cell"},{"key":"BFoncsis201425_CR25","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1172\/JCI70739","volume":"123","author":"D Inoue","year":"2013","unstructured":"Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T et al. Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. J Clin Invest 2013; 123: 4627\u20134640.","journal-title":"J Clin Invest"},{"key":"BFoncsis201425_CR26","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2010-05-283291","volume":"116","author":"WC Chou","year":"2010","unstructured":"Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 2010; 116: 4086\u20134094.","journal-title":"Blood"},{"key":"BFoncsis201425_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/leu.2012.262","volume":"27","author":"S Schnittger","year":"2013","unstructured":"Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013; 27: 82\u201391.","journal-title":"Leukemia"},{"key":"BFoncsis201425_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nrg1726","volume":"6","author":"JC Pearson","year":"2005","unstructured":"Pearson JC, Lemons D, McGinnis W . Modulating Hox gene functions during animal body patterning. Nat Rev Genet 2005; 6: 893\u2013904.","journal-title":"Nat Rev Genet"},{"key":"BFoncsis201425_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1182\/blood-2006-06-001149","volume":"109","author":"K Mrozek","year":"2007","unstructured":"Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD . Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109: 431\u2013448.","journal-title":"Blood"},{"key":"BFoncsis201425_CR30","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2013-02-483487","volume":"122","author":"SJ Kim","year":"2013","unstructured":"Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T . A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013; 122: 4086\u20134089.","journal-title":"Blood"},{"key":"BFoncsis201425_CR31","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1182\/blood-2009-04-216606","volume":"115","author":"C Bach","year":"2010","unstructured":"Bach C, Buhl S, Mueller D, Garcia-Cuellar MP, Maethner E, Slany RK . Leukemogenic transformation by HOXA cluster genes. Blood 2010; 115: 2910\u20132918.","journal-title":"Blood"},{"key":"BFoncsis201425_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491\u2013498.","journal-title":"Nat Genet"},{"key":"BFoncsis201425_CR33","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754\u20131760.","journal-title":"Bioinformatics"},{"key":"BFoncsis201425_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nature11632","volume":"491","author":"C Genomes Project","year":"2012","unstructured":"Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56\u201365.","journal-title":"Nature"},{"key":"BFoncsis201425_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1126\/science.1219240","volume":"337","author":"JA Tennessen","year":"2012","unstructured":"Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012; 337: 64\u201369.","journal-title":"Science"},{"key":"BFoncsis201425_CR36","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/bioinformatics\/btq293","volume":"26","author":"B Zeitouni","year":"2010","unstructured":"Zeitouni B, Boeva V, Janoueix-Lerosey I, Loeillet S, Legoix-ne P, Nicolas A et al. SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. Bioinformatics 2010; 26: 1895\u20131896.","journal-title":"Bioinformatics"},{"key":"BFoncsis201425_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/1471-2105-14-244","volume":"14","author":"H Zhang","year":"2013","unstructured":"Zhang H, Meltzer P, Davis S . RCircos: an R package for Circos 2D track plots. BMC Bioinformatics 2013; 14: 244.","journal-title":"BMC Bioinformatics"},{"key":"BFoncsis201425_CR38","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.","journal-title":"Sci Signal"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/oncsis201425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/oncsis201425","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/oncsis201425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T21:25:36Z","timestamp":1672953936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/oncsis201425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,7]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7]]}},"alternative-id":["BFoncsis201425"],"URL":"https:\/\/doi.org\/10.1038\/oncsis.2014.25","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,7]]},"assertion":[{"value":"22 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Belani declares an ownership interest in the Medical Oncology Associates of San Diego, intellectual property ownership with Atyr Pharma and is an adviser for Dendreon and Bayer. Dr Torkamani declares he is a co-founder and equity owner of Cypher Genomics, Inc. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}